In a groundbreaking move, Abu Dhabi’s Department of Health Abu Dhabi has granted early access to WINREVAIR, a cutting-edge medication for Pulmonary Arterial Hypertension (PAH). This initiative marks a pivotal moment, as Abu Dhabi becomes the first in the region to introduce this innovative treatment, bringing new hope to patients battling this life-threatening condition.
Dr. Asma Al Mannaei emphasized the significance of this step, stating, “Such initiatives reinforce Abu Dhabi’s position as a global healthcare leader.”
The Science Behind WINREVAIR
WINREVAIR represents a breakthrough in PAH management, targeting the disease at its core. Administered as a subcutaneous injection every three weeks, the medication disrupts harmful cellular growth in the pulmonary blood vessels, preventing narrowing and improving blood flow.
This approach not only reduces cardiovascular strain but also significantly enhances patient outcomes. Clinical trials have shown an 84% reduction in clinical worsening events and marked improvements in exercise capacity. Complementing standard PAH treatments, WINREVAIR has earned approval from both the FDA and Emirates Medical Association, cementing its role as a transformative therapy.
A Lifesaving Impact
PAH is a relentless and rare condition, affecting 15 to 60 individuals per million worldwide, predominantly women (70–80% of cases). Striking between the ages of 50 and 65, it often leads to heart failure if untreated.
The introduction of WINREVAIR is more than a medical advancement—it’s a lifeline. Combined with existing therapies, it offers patients over a decade of extended life expectancy.
Ashraf Mallak of MSD GCC hailed this collaboration, noting, “This partnership marks a new hope for patients living with this disease in the UAE.”
Abu Dhabi’s Vision in Healthcare
Pulmonary Arterial Hypertension is a formidable challenge, with blocked or damaged pulmonary vessels placing immense strain on the heart. Traditional treatments have offered limited relief, but WINREVAIR is rewriting the narrative.
Abu Dhabi’s proactive healthcare strategy is setting a benchmark not just regionally but globally. By prioritizing early access to innovative solutions like WINREVAIR, the emirate continues to lead with purpose, demonstrating its unwavering commitment to advancing patient care and medical innovation.
